Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
IPO Year: 2018
Exchange: NASDAQ
Website: vaccinex.com
10-K - VACCINEX, INC. (0001205922) (Filer)
NT 10-K - VACCINEX, INC. (0001205922) (Filer)
15-12G - VACCINEX, INC. (0001205922) (Filer)
EFFECT - VACCINEX, INC. (0001205922) (Filer)
EFFECT - VACCINEX, INC. (0001205922) (Filer)
EFFECT - VACCINEX, INC. (0001205922) (Filer)
EFFECT - VACCINEX, INC. (0001205922) (Filer)
EFFECT - VACCINEX, INC. (0001205922) (Filer)
EFFECT - VACCINEX, INC. (0001205922) (Filer)
EFFECT - VACCINEX, INC. (0001205922) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4/A - VACCINEX, INC. (0001205922) (Issuer)
Fastest customizable press release news feed in the world
ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer. Lead investigator and collaborator, Conor Steuer, MD from Winship Cancer Center at Emory University, will present results at the 2025 Annual Meeting of Clinical Oncology (ASCO)
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in "cold" tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting ne
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its decision to delist the Company's shares of common stock, par value $0.0001 per share (the "Common Stock"), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that on December 16, 2024, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq due to the Company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the Company has not been
Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer's disease. Treatment with pepinemab believed to slow cognitive decline due to Alzheimer's disease: Vaccinex reported final data from its SIGNAL-AD clinical trial at the Alzheimer's Association In
ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen (Grifols), Merus, Soleil, ThirdArc and Incyte, employing Vaccinex's ActivMAb® technology to generate antibodies to complex antigen targets. In addition, Vaccinex has signed agreements to provide Charles River Labs, OmniAb, Adimab and other undisclosed strategic partners with materials to facilitate their antibody discovery programs using transg
ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-negative, head and neck cancer (HNSCC). In a presentation at Society for Immunotherapy of Cancer's Annual Meeting (SITC) on November 8th, Vaccinex will present data from the Phase 2 KEYNOTE-B84 study (NCT04815720) for treatment of recurrent and metastatic disease
ROCHESTER, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex (NASDAQ:VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Vaccinex recently announced positive results of the phase 1b/2 study of its lead product, pepinemab, in early stages of Alzheimer's disease (AD). The purpose of this report is to share additional data demonstrating stage-specific biomarker and cognitive effects starting with Mild Cognitive Impairment (MCI), the very earliest diagnostic stage of AD, and following through to progression to later stages of mild dementia. Currently approved treatments for AD are designed to reduce expressio
ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer's disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, on October 31, 2024. Elizabeth Evans, PhD, Chief Operating Officer and Senior VP Discovery and Translational Medicine, will present results of the study in a podium presentation. Pres
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the "Existing Warrants") at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares. In consideration for the immediate exercise of the warrants for c
This live feed shows all institutional transactions in real time.
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13G - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13G - VACCINEX, INC. (0001205922) (Subject)
SC 13G/A - VACCINEX, INC. (0001205922) (Subject)